Chart Industries

Phase A — Understand the business

Lens 1 · Company Overview

Chart Industries designs, engineers and manufactures process technologies and equipment for moving and transforming gas/liquid molecules — what it brands the "Nexus of Clean" (clean power, water, food, industrials). It is, in plain terms, the cryogenic + heat-transfer + air/gas-handling equipment company that sits inside almost every LNG, industrial-gas, hydrogen, and CO2-capture value chain. FY2025 sales were $4,264.0M (2023: $3,352.5M; 2024: $4,160.3M). 62–63 manufacturing sites, >50 service centers, 11,777 employees, >10,000 customers.

Four reportable segments:

• Cryo Tank Solutions (14.6%) — bulk/microbulk/mobile cryogenic storage & distribution for industrial gases and LNG.
• Heat Transfer Systems (29.0%) — brazed-aluminum heat exchangers, cold boxes, the proprietary IPSMR® liquefaction process; the LNG/gas-processing engine. Also air-cooled heat exchangers + fans into HVAC, data centers, power, refining.
• Specialty Products (25.8%) — hydrogen/helium, carbon capture (CCC/DAC), water treatment (incl. PFAS), food & bev, aerospace, space, nuclear, marine, mining, lasers.
• Repair, Service & Leasing (30.6%) — aftermarket: parts, retrofits, 24/7 service, leasing, plus the Uptime™ digital monitoring platform and Ventsim™ mine-ventilation software (2,500+ mines).

Business model = highly-engineered, often custom, project-and-aftermarket equipment. Revenue recognition is ~77% over-time (percentage-of-completion) and ~23% point-in-time. Contracts often carry advance payments, LCs and performance bonds. Top-10 customers = 27% of sales in 2025; no single customer >10%. 58% of sales international. Built largely via M&A — the transformational $4.4B Howden acquisition (Mar 2023), which added the rotating-equipment / air-and-gas-handling franchise.

Lens 2 · Supply Chain

Upstream inputs → Chart → end customer, with named stakeholders:

• Raw-material inputs: aluminum (sheet/bar/plate/piping — special grades for brazed-aluminum heat exchangers), stainless steel, carbon steel, palladium oxide, valves, gauges, fabricated metal. Chokepoint: special-grade aluminum and compressors are single-/few-source, with long lead times, explicitly flagged as a supplier-concentration risk. Commodity inputs (Al, stainless, carbon steel) are tariff-exposed in 2026 — and tariffs were already a named drag on Q1-26 gross margin.
• Chart's own conversion: 150 facilities, ~12.9M sq ft (~8.9M owned). Manufacturing concentrated US + Europe (Heat Transfer), global for Cryo Tank / Specialty.
• Downstream customers (named end markets / buyer types): global industrial-gas majors (Air Liquide, Linde, Air Products-type producers/distributors — Chart both sells to and competes with their captive equipment arms); LNG EPC contractors and export-terminal developers (Chart equipment is in ~90% of global LNG projects per the acquirer's own diligence); data-center / HVAC / power buyers for air-cooled exchangers (a fast-growing Heat Transfer demand driver); hydrogen mobility via its 25% stake in HTEC.
• New chain signal: Chart began factoring trade receivables (limited recourse) in June 2025 — $42.2M sold in Q1-26. That is a working-capital/liquidity-management tell worth noting (see Lens 10).

Lens 3 · Competitive Advantages (moats)

• Process IP + installed base in LNG/cryo. The IPSMR®/IPSMR+® liquefaction process is pitched as lower-capex-per-ton than competing processes. ~160 years of hydrogen-equipment heritage and a large installed base feed a high-margin aftermarket. The acquirer's stated rationale leans on Chart being in ~90% of global LNG projects — that is the single strongest moat claim, though it is the buyer's framing.
• Aftermarket annuity. Repair, Service & Leasing is the largest segment (30.6% of sales) at the highest gross margin (44.3% FY2025). Servicing its own and competitors' equipment widens the moat. Uptime™ digital monitoring raises switching costs.
• Breadth + scale vs. regional point players. Management's repeated framing: competitors are "regionally focused or product-specific," Chart supplies the full range globally. Brazed-aluminum heat exchangers have only a handful of global (European/Asian) competitors.
• Caveat — IP is NOT the moat by the company's own admission. "No one [patent] is considered… of such importance that its expiration… would have a material adverse effect"; it depends on know-how and process, not patents. Patents expire 2026–2046. So the moat is scale + installed base + know-how, not a patent wall.
• Bargaining power is mixed. It sells to industrial-gas majors who also make some of their own equipment and to EPCs that competitively bid — pricing power is real in specialty/aftermarket, weaker in commoditized fabrication (air-cooled exchangers, "many smaller fabrication-only facilities").

Lens 4 · Segments

FY2025 vs FY2024 — sales, gross margin, operating income:

Read the trend carefully:

• Heat Transfer Systems is accelerating hard — sales +19.5%, op income +56% (+$131M), margin 22.5%→29.4% — driven by strong backlog conversion and data-center demand for air-cooled exchangers.
• Specialty Products decelerated on revenue (-1.4%) and margin (27.0%→25.7%) even as its orders exploded — Specialty orders +$518.9M to $2,080.9M and Specialty backlog +$789.3M to $2,677.4M (carbon capture, nuclear, HLNG, marine, space, mining). Revenue is lagging orders — backlog being built, not yet shipped.
• Repair, Service & Leasing softened (-5.0% sales, margin 47.0%→44.3%) because FY2024 had a high-margin emergency field-service repair + large aftermarket sale that didn't repeat.
• Consolidated operating margin collapsed 15.6%→8.4% — but that is almost entirely the $266M Flowserve termination fee + $22.8M deal costs sitting in Corporate ($(476.8)M vs $(184.0)M). Underlying segment operating income actually rose ($835M of segment op income in FY25 before Corporate, vs $831M in FY24). Geography: foreign 57.8% of sales.

Q1-26 segment detail: Cryo $145.6M / HTS $246.1M / Specialty $214.5M / RSL $278.6M; every segment's operating income fell YoY (HTS $66.9M→$32.1M; Specialty $48.3M→$8.4M) on lower volume, mix and tariffs.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1 2026, reported May 11, 2026)

The most recent print is weak on the P&L but the backlog is the opposite:

• Sales $884.8M, down 11.7% YoY ($1,001.5M Q1-25) — declines across all four segments.
• Gross margin 28.4% vs 33.9% — compressed by lower volume, unfavorable product mix, and tariffs on certain products (explicitly cited).
• Operating income $52.6M vs $152.3M. Net loss attributable to common of $(17.1)M, $(0.36) diluted EPS, vs +$49.5M / +$0.95 a year ago. (FY2025 full year: net income to common $13.5M / $0.30 diluted EPS, depressed by the $266M termination fee; ex one-timers, FY2025 op income was ~$647M-equivalent. Adjusted EBITDA FY2025 ~$1.01B, 23.8% of sales.)
• Balance-sheet / cash flags (important): operating cash flow was $(248.0)M used in Q1-26 (vs $(60.0)M Q1-25) — Q1 is seasonally working-capital-heavy, but unbilled contract revenue rose to $1,045.6M and accounts payable fell $203.7M. Net debt rose to ~$3,519M (long-term debt $3,786.7M; cash $267.9M) as the revolver was drawn $498.9M. Effective tax rate 46.8% (one-off, audit settlement + foreign WHT) explains some of the loss optics.
• Orders $1,280.3M; total backlog $6,282.9M (vs $5,143.6M a year ago, +22%). Remaining performance obligations $6,282.9M, ~42% to convert in 12 months.
• Market reaction is muted and deal-pinned: the stock sits at ~$208.50 (June 26, 2026) against the $210 cash price — the print barely matters because the equity is a bond-like claim on deal close.

Unusual vs. its own history: the net loss and the negative operating cash flow would be alarming standalone signals; here they are a mix of (i) genuine cyclical/tariff softness in the new-equipment lines and (ii) deal-pendency distortion (the company is run "in the ordinary course," buybacks frozen).

Lens 6 · Earnings Calls (sentiment trend)

No transcripts/ on the research shelf (transcripts=0) — so this is web/derived. Sentiment arc over the last ~4 quarters is dominated by the deal, not operations:

• Q1 2025 (May 2025): results "miss expectations" — soft start to the year on timing.
• June 2025: announces Flowserve "merger of equals" (~$19B EV all-stock) — tone shifts entirely to portfolio/strategy.
• July 28–29, 2025: terminates Flowserve, signs Baker Hughes $210 cash ("Superior Chart Proposal") — tone becomes deal-execution + regulatory cadence.
• Q2/Q3 2025 + Q4/FY (Feb 2026): delivered $1.01B adjusted EBITDA for the year; commentary centers on backlog strength (Specialty, data-center HTS) and the regulatory timeline. CEO Jill Evanko announced departure (Nov 2025) to Duravant, staying as senior advisor through close. The "things they stopped saying": standalone capital-return / medium-term-target talk is gone — replaced by close-timing language. Recurring phrase: deal "on track to close mid-2026."

Lens 7 · Comps

Read: the $13.6B EV / ~$1.01B FY25 adj. EBITDA ≈ 13.5x EV/EBITDA take-out multiple ÷ $1.01B adj. EBITDA ] — squarely in line with where flow-control/industrial peers (FLS ~14.3x, IR ~14.5x, DOV ~15.6x) trade, i.e. BKR is paying a fair-to-slightly-below-peer multiple, not a stretch. That matters for deal durability: it is not a price a buyer walks away from on second thoughts, and it limits the odds of a topping bid (none has emerged).

Lens 8 · Stock-Price Catalysts (last ~5 years, moves >5%)

Mostly + the deal record:

• Mar 2023 — Howden close + financing: the $4.4B debt-and-equity-funded deal reset the leverage and share-count story; high volatility around the raise.
• 2024 — convertible-preferred overhang + de-levering: the 6.75% Series B mandatory convertible (issued Dec 2022 for Howden) was a persistent dilution overhang until it converted to ~2.84M shares in Dec 2025.
• June 4, 2025 — Flowserve "merger of equals" announced (~$19B EV): both stocks initially up on scale narrative, then wobbled.
• July 28–29, 2025 — the decisive move: Flowserve terminated, Baker Hughes $210 all-cash signed — a ~22% premium to the undisturbed price. This is the catalyst that converted GTLS into an arb.
• Nov 6, 2025 — HSR clearance (US antitrust gate cleared) — spread tightened.
• May–June 2026 — EU Phase-I review: spread sensitivity now keys entirely off EU headlines (remedies submitted May 21; decision window late June; deadline July 10). Pattern: pre-deal, GTLS reacted to LNG/order cycles, leverage, and dilution; post-July-2025 it reacts only to deal-completion probability. The market reacts to regulatory and macro/energy-policy news for this name far more than to a single customer.

---

Phase C — Judge people & books

Lens 9 · Management

• Track record (strong, M&A-built): Jill Evanko ran Chart ~9 years (CEO from 2018), architecting the pivot to a clean-energy/industrial molecule-handling platform and executing the transformational Howden deal — then selling the company twice in two months (Flowserve MoE → the superior $210 BKR cash bid). Crystallizing a ~22% cash premium for holders is a genuinely shareholder-friendly capital-allocation outcome.
• Tenure & skin in the game / transition: Evanko departs early 2026 to become CEO of Duravant, staying as senior advisor to Chart through deal close to ensure continuity; the board names an interim CEO from within. Insider-ownership detail: n/a (no insider-transactions.csv on shelf).
• Capital-allocation history: levered up for Howden ($4.4B), then deleveraging discipline — explicit financial policy of no material cash acquisitions until below 2.5x net leverage; $250M buyback authorized Dec 2024 (now frozen under the merger covenant); mandatory-preferred converted Dec 2025, removing the 6.75% dividend drag. ROE/ROIC depressed in FY25 by the termination fee; underlying segment returns solid (HTS op margin 29.4%).
• Red flags: the back-to-back merger flip-flop (agree to Flowserve, pay it $266M to walk, take BKR cash 8 weeks later) is unusual and drew stockholder M&A litigation (two NY suits, since mooted by supplemental disclosures). Not fraud — but it shows a board willing to break a signed deal for a better number (good for this holder, a governance data point generally). No related-party or comp scandals surfaced.
• Archetype: professional manager / serial acquirer-integrator, not founder-operator — appropriate for a roll-up that is now being rolled up into a larger strategic (BKR).

Lens 10 · Forensic Red Flags

Acting as a forensic analyst — grounded in filings:

• Revenue recognition (watch): ~77% of revenue is over-time / cost-input percentage-of-completion — inherently estimate-driven (cost-to-complete judgment). Unbilled contract revenue $1,045.6M (a contract asset) is large and growing faster than sales ($986.4M at YE25; $735.1M at YE24) — i.e., revenue is being recognized ahead of billing, which is normal for project work but is the classic place to watch for aggressive POC. The company itself flags that inefficiency-driven cost revisions are expensed when known.
• Cash vs. earnings divergence (real): FY2025 operating cash flow $292.7M but that includes the $258M BHI termination-fee receipt — strip it and underlying OCF was ~$35M against $38.8M continuing net income, with a $219M working-capital drag from unbilled contract revenue. Backlog conversion is consuming cash. Q1-26 OCF was $(248.0)M. This is the single most important "quality" caveat — earnings are not converting to cash while the order book builds.
• Receivables factoring (new, June 2025): Chart started selling trade receivables with limited recourse ($42.2M in Q1-26) — a liquidity-management move that flatters reported operating cash flow vs. organic collection. Worth flagging precisely because it began the same year as the deal saga and the cash drag.
• Goodwill & intangibles (large, but tested clean): goodwill + indefinite-lived intangibles were $3,724.0M = 38.0% of total assets; Step-1 tested, no impairment at Oct 1, 2025. A Howden-overhang risk if industry conditions deteriorate, but not an issue today.
• Leverage: total debt $3,786.8M at coupons of 7.5% secured / 9.5% unsecured / ~6.2% term loan; ~3.5x gross / ~3.2x net on $1.01B adj. EBITDA. In compliance with all covenants at both YE25 and Q1-26. Notes carry a 101% change-of-control put — relevant to the BKR close mechanics.
• SBC: modest ($17.2M FY25) — not flattering non-GAAP materially.
• Off-balance-sheet: the HTEC put option — BDT&MSD can put HTEC shares to Chart for $323.0M ($51.20/share, accreting 11.25% after yr-3); not expected to hit before 2028; a contingent claim BKR inherits.
• Internal controls: effective; Deloitte unqualified opinion FY2025.

Regulatory findings (required):

• SEC Litigation Releases & AAERs: none. Verified via SEC EDGAR EFTS (LR + AAER) for 2021-06-30→2026-06-30 — 0 findings.
• 10-K Item 3 (Legal Proceedings): "Ordinary Course Litigation" only — contract/product-liability/tax/employment/environmental claims incidental to business, none expected to be material.
• Merger litigation: two NY stockholder suits (McDaniels, Johnson, Sept 11 2025) alleging an incomplete proxy — mooted by supplemental 8-K disclosures Sept 25 2025; only a mootness-fee demand remains. Routine deal litigation, not substantive.
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/penalty hits surfaced for "Chart Industries" beyond the antitrust review of the BKR acquisition itself.
• Net: No material regulatory or forensic-accounting findings — verified via SEC EDGAR EFTS (LR, AAER), 10-K Item 3, and web search as of 2026-06-30. The only "regulatory" item that matters is the EU merger review (a deal gate, not misconduct).

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

This is a merger-arb, so the relevant projection is a deal-outcome distribution, not a 3-year EPS path. I give both.

(a) Deal-value / spread model (the actual trade) — all-cash $210.00/share vs. last ~$208.50 (June 26, 2026):

• Gross spread ≈ $1.50/share ≈ 0.72%.
• Time to close ≈ ~1 month (target July 2026; EC deadline July 10).
• Annualized ≈ ~9–11% if it closes in ~30 days — before any deal-break downside.
• Break downside: undisturbed pre-deal price was ~$172 (implied by the "22% premium to $210" framing) ]. A clean break could see the stock fall toward ~$170–180 (offset somewhat by the strong standalone backlog and a possible re-rate as a clean-energy/LNG/data-center equipment compounder) — call it ~$30–40 of downside vs ~$1.50 of upside. Classic late-stage-arb asymmetry: small carry, large tail if the last gate fails.

(b) Standalone EPS path (the floor case, if the deal somehow broke):

• FY2025 base: diluted EPS $0.30 GAAP (distorted by the $266M fee); normalized continuing EPS ~$3.50–4.00 ex-termination-fee/ex-deal-costs.
• FY2026 base ~$5.00–5.50, bull ~$6.00+, bear ~$4.00: drivers — backlog of $6.28B (RPO 42% in 12 months) supports mid-single-digit revenue growth as Specialty/HTS orders convert; offsets = tariff margin pressure (Q1-26 GM −5.5pts), high interest cost ($300M/yr), negative near-term operating cash conversion. Margin mix improves as Specialty backlog ships.
• FY2027–28: low-double-digit EPS growth if orders keep converting and tariffs ease. High uncertainty — the order book is real but cash conversion and tariffs are the swing factors.

No forecast.ts create (per --watchlist rules + the fact that the binding outcome here is a deal close, not an EPS line). If forced to log one binary, the scoreable forecast would be: "GTLS / Baker Hughes merger closes at $210 cash by 2026-09-30, p≈0.90" — left unlogged in this unattended sweep.

Lens 12 · Bull vs Bear

Bull (the arb / deal-completes case):

• All-cash $210, board + 100% stockholder approval secured (Oct 6 2025), US HSR cleared (Nov 6 2025) — only the EU Phase-I gate remains, and remedies have been submitted with both sides reiterating a July 2026 close. BKR is paying a fair ~13.5x EBITDA, has $325M synergy logic and double-digit Year-1 EPS accretion — strong strategic commitment, low walk-away risk. $500M reverse-termination fee if BKR fails to get antitrust clearance caps the acquirer's incentive to abandon. Underlying business gives a high floor: record $6.28B backlog, $1.01B adj. EBITDA, data-center + LNG + Specialty secular demand.
• Contrarian bull: the standalone business is better than the deal-pinned tape suggests — if the EU somehow blocked it, a re-rate of a clean-energy/LNG/data-center equipment leader with a 22%-richer order book could limit the downside materially below the naive "$172 undisturbed" number.

Bear (deal-break / permanent-impairment case):

• EU is a live risk: the Commission can reject the remedies, demand more, or open a 4-month Phase-II investigation. A Phase-II would push close into late-2026/2027, crushing the annualized return and raising MAC/financing risk.
• Financing condition: BKR must actually fund — the merger agreement's forward-looking risks explicitly include "the possibility that Baker Hughes may not be able to obtain sufficient financing".
• Standalone deterioration is real, not just optical: Q1-26 sales −11.7%, GM −5.5pts on tariffs/mix, OCF deeply negative, net debt rising, leverage ~3.2x, receivables factoring started — a broken deal hands you a levered, cash-consuming cyclical with a CEO who just left.
• Expectations baked in price: at ~$208.50 the market prices ~90%+ deal-completion odds — there is essentially no operational upside left and a 15–20% air-pocket below on a break.
• Pre-mortem (18 months out, thesis broke): the EU opened Phase II over LNG-equipment/heat-exchanger concentration, remedies proved insufficient, the deal slipped past the (extended) outside date or collapsed; GTLS reset to the high-$170s/low-$180s into a softening, tariff-hit new-equipment cycle with negative cash conversion — the arb "carry" of $1.50 was dwarfed by a $30+ drawdown.

Are multiples too high? Not for the buyer — ~13.5x EBITDA is reasonable vs peers (FLS 14.3x, IR 14.5x, DOV 15.6x). The risk is regulatory/timing, not valuation.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull (i.e., the "just collect the spread" case):

• What structurally breaks the trade: the only thing standing between $208.50 and $210 is one European regulator, and the EC has explicitly reserved the right to go to Phase II — a 4-month deep-dive — over exactly the overlaps a $13.6B energy-equipment combination creates (LNG heat exchangers, compression, flow). The market is treating a binary regulatory decision as ~90% done; shorts would argue the tail is fatter than the 0.7% spread implies.
• Revenue concentration / cyclicality: new-equipment demand is cyclical and capex-dependent; LNG/energy project timing already slipped in 2025, and tariffs are actively compressing margins now. On a break you own that cycle, levered.
• Cash quality: the bear's sharpest point — earnings aren't converting to cash (ex-fee FY25 OCF ~$35M; Q1-26 OCF −$248M), unbilled contract revenue is ballooning, and the company resorted to receivables factoring. A standalone Chart at 3.2x leverage with negative working-capital trends and 7.5–9.5% notes is not a fortress.
• Most dangerous competitor bulls underrate: for the aftermarket annuity thesis, the industrial-gas majors' captive equipment/service arms (Linde, Air Liquide, Air Products) plus Baker Hughes' own rotating-equipment franchise — i.e., the synergy logic cuts both ways; a regulator could see the combination as foreclosing third-party equipment buyers.
• Worst capital-allocation optics: paying $266M to break the Flowserve deal eight weeks after signing it — great for the seller who got $210, but a sign of a board that will reverse course, and a reminder that signed merger agreements are not destiny.
• What permanently impairs: a Phase-II block + a tariff-driven margin reset + the cyclical roll-over arriving together. Plausibility: low-but-not-trivial (the EU has not blocked, HSR cleared, remedies are in) — which is precisely why the spread is thin and the asymmetry is ugly.

Lens 14 · Management Questions (ordered by information value)

1. What specific EU remedies did Baker Hughes offer, and does the Commission's market test (customers/competitors) point to Phase-I clearance or a Phase-II referral? (the entire trade hinges on this)
2. If the EC signals Phase II, what is the revised outside date and at what point does either party have a walk right or a financing re-confirmation obligation?
3. What is Baker Hughes' committed financing structure for the $210 cash, and is it subject to any market-out?
4. Bridge FY2025 adjusted EBITDA of ~$1.01B to the ~$35M of underlying (ex-termination-fee) operating cash flow — what normalizes in 2026?
5. How much of the $219M FY25 / ongoing unbilled-contract-revenue build reverses to cash, and over what timeline as Specialty backlog ships?
6. What is the run-rate tariff impact on gross margin in 2026, and how much is recoverable via price/surcharge vs. permanent?
7. How durable are the Specialty orders (carbon capture, nuclear, space, marine) — firm POs with advances, or option-heavy/cancellable?
8. What share of the $6.28B backlog carries cancellation/termination protection, and what is the historical cancellation rate?
9. On the HTEC put ($323M, accreting 11.25% post-2028): base-case probability of exercise, and how does BKR view that liability?
10. With the $250M buyback frozen and the deal pending, what is the de-levering path on the $3.79B debt if (hypothetically) the deal broke?
11. What is the interim-CEO mandate and retention plan for key engineering/commercial talent through close (post-Evanko)?
12. How exposed is the order book to US energy-policy / LNG-permitting shifts and to China tensions (58% international)?
13. What is the data-center demand trajectory for Heat Transfer air-cooled exchangers, and is it structural or a 2024–25 spike?
14. Any goodwill-impairment risk to the $3.7B (38% of assets) if the cycle softens and the deal does not close?
15. What contingencies exist if palladium-oxide / special-grade-aluminum single-source supply is disrupted under tariffs?

---